Diagnostics AI
By
Is Aidoc’s $150M Bet on CARE™ and aiOS™ Resetting the Future of Clinical AI for 100 Million Patients?
Key Highlights CARE™ Foundation Model Redefining Standards in Clinical AIAidoc’s CARE™ model—now backed by $150 million in new…
Is Thermo Fisher’s $10B Q2 Surge the Inflection Point for AI-Powered Biopharma? How Will It Reshape the Life Sciences Landscape?
Key Highlights Financial Resilience and Strategic MarginsThermo Fisher Scientific’s Q2 2025 report showcases its fortress-like financial discipline. With…
Can Clairity’s FDA-Approved AI Breast Cancer Prediction Tool Transform How We Predict Breast Cancer Risk Over 5 Years?
Key Highlights: AI-Driven Risk Prediction: A Breakthrough in Preventive OncologyBoston-based Clairity received FDA de novo authorization for Clairity…
Can VUMC’s New AI Technologies Reshape Cancer Diagnostics and Immunotherapy for Millions?
Key Highlights AI-Powered MSI-SEER Revolutionizes Tumor ProfilingVanderbilt University Medical Center (VUMC), in collaboration with Mayo Clinic and leading…
Can Harvard’s FaceAge and Emerging AI Facial Recognition Apps Revolutionize Disease Prediction and Personalized Care in Biopharma and Healthcare?
Key Highlights: AI Facial Recognition as a Medical BiomarkerDeveloped at Harvard Medical School, the FaceAge algorithm analyzes photos…
Is Aptitude’s $9M BARDA Partnership and Metrix Filovirus Panel the Breakthrough for Fast, Decentralized Detection of Ebolavirus and Marburgvirus?
Key Highlights BARDA Partnership Accelerates Filovirus Diagnostic InnovationAptitude’s second collaboration with BARDA brings $9 million in new federal…
